AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00437840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.
Trial: NCT00019786
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02752763
Drug: %40 diluted Autologous serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum that obtained after centrifugation of blood sample
Trial: NCT02752763
Drug: Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative free artificial tears is a group naming for drops commonly used for drye disease
Trial: NCT02166814
Drug: Fimasartan and Rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02166814
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00751907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo daily for 4 months
Trial: NCT03250494
Drug: combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
Trial: NCT02803229
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo provided for placebo arm
Trial: NCT00415844
Drug: ELC200 (carbidopa+levodopa+entacapone)
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01684163
Drug: GLYX-13 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 10 mg/kg into arm.
Trial: NCT02099695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The quantity of tablets will increase due to the absence/ lack of therapeutic response.
Trial: NCT00777413
Drug: Minocycline 100mg Tablets
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01881113
Drug: AC-170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT01881113
Drug: AC-170 0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT00673387
Drug: placebo-P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice a day
Trial: NCT00673387
Drug: placebo-M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, twice a day
Trial: NCT00786994
Drug: Placebo (petroleum jelly)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical use once or twice daily
Trial: NCT00004089
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05027243
Drug: Xeomin® (Merz)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
Trial: NCT01080443
Drug: Mycophenolate Mofetil Capsule 250 mg
RxNorm normalized name: mycophenolate mofetil Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Trial: NCT00969631
Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
Trial: NCT00039520
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04223531
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
Trial: NCT00739986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV x 3 days
Trial: NCT03802955
Drug: ADG106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
Trial: NCT03542955
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonsteroidal anti-inflammatory drug used as standard therapy
Trial: NCT00804713
Drug: BST
RxNorm normalized name: Labstix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
Trial: NCT00804713
Drug: TST
RxNorm normalized name: OATSTRAW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer TB Skin test (TST)
Trial: NCT03589950
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Trial: NCT03456154
Drug: Botox Injectable Product
RxNorm normalized name: Botox Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60u will be used at 3 sites of masseter muscle, on each side of the face
Trial: NCT02456558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
Trial: NCT02799368
Drug: CJ Plasma Solution A Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
Trial: NCT02799368
Drug: CJ 0.9% Normal Saline Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
Trial: NCT03598868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation : Placebo for week 1,2,4,6
Trial: NCT00784875
Drug: LY2624803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg, oral capsule, once nightly before bedtime
Trial: NCT00784875
Drug: LY2624803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg, oral capsule, once nightly before bedtime
Trial: NCT00784875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo (capsule or tablet), once nightly before bedtime
Trial: NCT03008876
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infants receive acetaminophen for treatment of their PDA
Trial: NCT03008876
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
Trial: NCT02629354
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02629354
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00719849
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/Kg Day -6
Trial: NCT03188666
Drug: REGN2477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
Trial: NCT03188666
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
Trial: NCT00002639
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01529346
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
Trial: NCT04353765
Drug: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per authorized FDA label in advanced RCC
Trial: NCT02789397
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
Trial: NCT01375153
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl administered as a continuous intravenous infusion during four hours
Trial: NCT01951885
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
Trial: NCT01951885
Drug: Methotrexate (low dose)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
Trial: NCT02560766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT01878461
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01878461
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03990597
Drug: Wound Dressing Material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied StrataXRT topically
Trial: NCT02885597
Drug: Juanbi pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g, twice a day, 3month, oral
Trial: NCT02885597
Drug: Juanbi pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g, twice a day, 3month, oral
Trial: NCT02885597
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg, once a week, 3 month, oral
Trial: NCT00496353
Drug: MK2461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2461 treatment, bid, 28-day
Trial: NCT00440024
Drug: Dove Mild Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion
Trial: NCT01687478
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT01687478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT00002865
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002865
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00440024
Drug: Dove Facial Moisturizer
RxNorm normalized name: Dove DermaSeries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing cream - Dove facial moisturizer with SPF 15
Trial: NCT00002865
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002865
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04493281
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation
Trial: NCT01007942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Trial: NCT01533766
Drug: CombiflexOmega
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously over 5 days infusion
Trial: NCT01081535
Drug: ketorolac, fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous PCA
Trial: NCT04549935
Drug: Topical Prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care topical drop treatment
Trial: NCT03300544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03300544
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03300544
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00051987
Drug: VELCADE TM (bortezomib) for Injection, or PS-341
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393806
Drug: GSK3772847
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
Trial: NCT03393806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially sourced sterile normal saline will be provided as Placebo
Trial: NCT02649985
Drug: [F-18]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT02649985
Drug: [C-11]PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT01675661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
Trial: NCT02435095
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Trial: NCT02435095
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole).
Trial: NCT01050608
Drug: 62% ethanol based hand cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDC based guidelines with regard to utilization in the health care environment the nest
Trial: NCT03806374
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl
Trial: NCT02670954
Drug: Dexmedetomidine, tramadol and flurbiprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02670954
Drug: tramadol and flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006055
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04269538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC dosing
Trial: NCT00977379
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
Trial: NCT00977379
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
Trial: NCT02118090
Drug: DHA-PP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
Trial: NCT00787059
Drug: Ad5.hAC6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
Trial: NCT00556400
Drug: Placebo - sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04561375
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 µg tablet of sublingual sufentanil
Trial: NCT04561375
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 µg fentanyl
Trial: NCT01386151
Drug: Keratinocyte Growth factor
RxNorm normalized name: Keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
Trial: NCT01386151
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal (0.9%) saline will be used as a placebo.
Trial: NCT00654966
Drug: Urotensine II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Trial: NCT01359969
Drug: rhC1INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
Trial: NCT00593736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
Trial: NCT01268332
Drug: Non-medicated Intravaginal Ring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
Trial: NCT01123135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03825341
Drug: Hydroxyurea Oral Capsule
RxNorm normalized name: hydroxyurea Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
Trial: NCT00057421
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002608
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01067235
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
Trial: NCT00138970
Drug: Zenapax®, CellCept® and prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00138970
Drug: Sandimmun Neoral®, CellCept® and prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02595749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00918840
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Trial: NCT00002883
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01716689
Drug: oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg daily
Trial: NCT04260438
Drug: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fed condition